Effects of linezolid combined with meropenem on blood gas indicators and serum ANXA1 level in patients with severe pneumonia

Xu Zhenlin; Li Yixin; Zhao Guoping; Wu Shilang; Lin Jiancong

doi:10.3969/j.issn.1671-6450.2025.03.012

Abstract：Objective To investigate the effects of linezolid combined with meropenem on blood gas indicators and serum annexin A1(ANXA1)level in patients with severe pneumonia(SP).Methods A total of 100 patients with SP admitted to the Emergency Medicine Department of the 910th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army from June 2021 to December 2023 were selected as the research objects.the patients were random-ly separated into a meropenem group(50 cases)and a combination group(50 cases).The meropenem group was treated with meropenem,while the Combination group was treated with meropenem combined with linezolid.Both groups were trea-ted continuously for2 weeks.The clinical efficacy,clinical indicators,ANXA1,blood gas indicators,lung function indicators,serum inflammatory factors,and adverse reactions of the two groups after treatment were observed.Results After treat-ment,the total clinical effective rate of the Combination group was 96.00％(48/50),while the total effective rate of the mero-penem group was 74.00％(37/50),the Combination group was obviously higher than the meropenem group(Z/P=9.490/0.002).The fever disappearance time,sputum disappearance time,sputum bacterial conversion time,hospitalization time in the Combination group were obviously reduced compared to the meropenem group(t/P=15.915/＜0.001,6.864/＜0.001,8.283/＜0.001,8.336/＜0.001).The levels of arterial oxygen partial pressure(PaO2),arterial oxygen saturation(SaO2),and transforming growth factor-β(TGF-β)were obviously increased in both groups compared to before treatment,while the Combination group was obviously higher than the meropenem group(t/P=11.628/＜0.001,3.365/＜0.001,11.679/＜0.001).The lung function indicators[maximum mid expiratory flow(MMEF),peak expiratory flow(PEF),and forced vital capacity(FVC)]of two groups were obviously improved compared to before treatment,and the Combination group was obviously higher than the meropenem group(t/P=5.636/＜0.001,4.162/＜0.001,2.851/0.005).The interleukin-1β(IL-1β),procalcitonin(PCT),and C-reactive protein(CRP),Annexin Al were obviously reduced compared to before treatment,and the Combination group was obviously lower than the meropenem group(t/P=3.902/＜0.001,4.576/＜0.001,20.185/＜0.001,21.947/＜0.001,6.907/＜0.001).The total incidence of adverse reactions(rash,dizziness,nausea,diarrhea)in the Combination group was 6.00％,while in the meropenemgroup it was 12.00％,there was no obvious difference in adverse reactions between the two groups(P＞0.05).Conclusion The combination of linezolid and meropenem in treating SP can improve the clinical efficacy of patients,reduce inflammatory reactions and ANXA1 levels,improve clinical symptoms,blood gas indicators,and lung function indicators,and has high safety.